FOSTER CITY, CA--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced positive topline results from its pivotal Phase 3 MARCH study evaluating LIVMARLI® (maralixibat) oral solution in 93 patients with progressive familial...
Cerexa to be acquired by Forest Laboratories for $480 million plus potential $100 million milestone payment
News | 12. 14. 2006
Cerexa
Cerexa Inc. today announced it has entered into a definitive agreement to be acquired by Forest Laboratories Inc. (NYSE: FRX) for $480 million plus a potential $100 million milestone payment.
